MedTrace Logo

Effect and Tolerance of a Probiotic-based Medical Device Administered to Patients With Irritable Bowel Syndrome

NCT04324658 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 119

Last updated 2020-09-29

No results posted yet for this study

Summary

This is an observational, open, longitudinal, multicentre study conducted in France.

The study plans to enrol 119 patients with irritable bowel syndrome who will be included by about 50 general practitioners or gastroenterologists consulting in private offices. The treatment, Lactiplus® is a medical device, in the form of capsules containing L. gasseri LA806. The main objective of the study is to assess the effect of a 4-week treatment with the medical device on abdominal pain.

Conditions

  • Irritable Bowel Syndrome

Interventions

DEVICE

Lactiplus

capsules containing L. gasseri LA806

Sponsors & Collaborators

  • PiLeJe

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-30
Primary Completion
2020-06-26
Completion
2020-06-26

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04324658 on ClinicalTrials.gov